Phenols
Apexbio Technology LLC Nafcillin Sodium 7177-50-6 5g
Nafcillin Sodium (7177-50-6) is a small-molecule inhibitor targeting -lactamase It is designed to reversibly inhibit -lactamase thereby preventing bacterial resistance mediated by hydrolysis of -lactam antibiotics Nafcillin Sodium exerts its biological activity primarily through reversible inhibition of -lactamase In in vitro studies Nafcillin Sodium demonstrates inhibitory activity with an IC50 value of approximately 33 mM Based on these pharmacological properties Nafcillin Sodium holds research potential in investigating -lactamase-mediated antibiotic resistance mechanisms evaluating therapeutic combination strategies and studying bacterial susceptibility profiles
Chem Service Inc Catechol | 120-80-9 | MFCD00002188 | 1 g
This item has a minimum order quantity of 3 per supplier requirements
Catechol | Purity: 99.5% | Mol Wt: 110.11 | 120-80-9 | MFCD00002188 | 1 g
![eMolecules 1065010-87-8 | Potassium Cyclopropyltrifluoroborate | Accela ChemBio (ASD) | MFCD09265031 | 147.980 | C3H5BF3K | 95.000 | [K+].F[B-](F)(F)C1CC1 | 25g | 454121313](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000159440.jpg-250.jpg)
eMolecules 1065010-87-8 | Potassium Cyclopropyltrifluoroborate | Accela ChemBio (ASD) | MFCD09265031 | 147.980 | C3H5BF3K | 95.000 | [K+].F[B-](F)(F)C1CC1 | 25g | 454121313
Potassium Cyclopropyltrifluoroborate | Accela ChemBio (ASD) | 1065010-87-8 | MFCD09265031 | 147.980 | C3H5BF3K | 95.000 | [K+].F[B-](F)(F)C1CC1 | 25g | 454121313
eMolecules 50270-27-4 | 2,4,6-Trichloropyrimidine-5-carbaldehyde | ChemScene | MFCD02257700 | 211.430 | C5HCl3N2O | 98.000 | Clc1nc(Cl)c(C=O)c(Cl)n1 | 25g | 536836813
2,4,6-Trichloropyrimidine-5-carbaldehyde | ChemScene | 50270-27-4 | MFCD02257700 | 211.430 | C5HCl3N2O | 98.000 | Clc1nc(Cl)c(C=O)c(Cl)n1 | 25g | 536836813
eMolecules 157759-50-7 | Bromo-PEG1-CH2CO2tBu | Combi-Blocks, Inc. | MFCD28122952 | 239.109 | C8H15BrO3 | 95.000 | CC(C)(C)OC(=O)COCCBr | 5g | 797016969
Bromo-PEG1-CH2CO2tBu | Combi-Blocks, Inc. | 157759-50-7 | MFCD28122952 | 239.109 | C8H15BrO3 | 95.000 | CC(C)(C)OC(=O)COCCBr | 5g | 797016969
Apexbio Technology LLC MGCD-265 875337-44-3 10mM (in 1mL DMSO)
MGCD-265 (CAS 875337-44-3) is a multi-targeted ATP-competitive small molecule inhibitor primarily targeting c-Met and the vascular endothelial growth factor receptors VEGFR1 VEGFR2 and VEGFR3 with IC50 values of 1 nM 3 nM 3 nM and 4 nM respectively In preclinical non-small cell lung cancer (NSCLC) xenograft models including models with TKI-resistant EGFR T790M mutations MGCD-265 in combination with agents such as paclitaxel docetaxel or erlotinib demonstrated enhanced antitumor activity and antiangiogenic effects compared to monotherapy MGCD-265 has been investigated in phase I clinical trials as a single agent and in combination with docetaxel or erlotinib in patients with advanced solid tumors